FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrew Norman

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Stephen M Edwards; D G R Evans; Q Hope; Andrew R Norman; Yolanda Barbachano; Sarah Bullock; Zsofia Kote-Jarai; Julia Meitz; Alison Falconer; Peter Osin; Cyril Fisher; Matthew J Guy; Sameer Jhavar; A L Hall; L T O'Brien; B N Gehr-Swain; R A Wilkinson; M S Forrest; David P Dearnaley; A T Ardern-Jones; E C Page; Douglas F Easton; Rosalind A Eeles
Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
Jennifer L Glendenning; Yolanda Barbachano; Andrew R Norman; David P Dearnaley; Alan Horwich; Robert A Huddart
Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer.
D J Watkins; Ian Chau; David Cunningham; Satvinder S Mudan; N Karanjia; Gina Brown; Sue Ashley; Andrew R Norman; A Gillbanks
Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrew Norman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Stephen M Edwards; D G R Evans; Q Hope; Andrew R Norman; Yolanda Barbachano; Sarah Bullock; Zsofia Kote-Jarai; Julia Meitz; Alison Falconer; Peter Osin; Cyril Fisher; Matthew J Guy; Sameer Jhavar; A L Hall; L T O'Brien; B N Gehr-Swain; R A Wilkinson; M S Forrest; David P Dearnaley; A T Ardern-Jones; E C Page; Douglas F Easton; Rosalind A Eeles
Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
British journal of cancer 2010;103(6):918-24.
2010: Jennifer L Glendenning; Yolanda Barbachano; Andrew R Norman; David P Dearnaley; Alan Horwich; Robert A Huddart
Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer.
Cancer 2010;116(10):2322-31.
2010: D J Watkins; Ian Chau; David Cunningham; Satvinder S Mudan; N Karanjia; Gina Brown; Sue Ashley; Andrew R Norman; A Gillbanks
Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.
British journal of cancer 2010;102(2):255-61.
2009: Naureen Starling; Sheela Rao; David Cunningham; Tim Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqui Oates; Andrew R Norman
Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(23):3786-93.
2009: Alex Leary; Laura Assersohn; David Cunningham; Andrew R Norman; Geoffrey Chong; Gina Brown; Paul J Ross; C Costello; L Higgins; Jacqui Oates
A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.
Cancer chemotherapy and pharmacology 2009;64(3):455-62.
2009: Clare Moynihan; Andrew R Norman; Yolanda Barbachano; L Burchell; Robert A Huddart; David P Dearnaley; Alan Horwich
Prospective study of factors predicting adherence to medical advice in men with testicular cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2144-50.
2009: Ian Chau; Andrew R Norman; David Cunningham; Jacqui Oates; R Hawkins; Tim Iveson; Marianne Nicolson; P Harper; Matt Seymour; Tamas Hickish
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(5):885-91.
2009: V Formica; Andrew R Norman; David Cunningham; Andrew Wotherspoon; Jacqui Oates; Geoffrey Chong
Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients.
Acta haematologica 2009;122(4):193-9.
2008: David Cunningham; Naureen Starling; Sheela Rao; Tim Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqui Oates; Andrew R Norman
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
The New England journal of medicine 2008;358(1):36-46.
2007: Usman Khalid; Andrew R Norman; H J N Andreyev
Elevated C-reactive protein levels are not a feature of uncomplicated radiation-induced bowel injury.
European journal of cancer care 2007;16(4):346-50.
2007: V Formica; Andrew Wotherspoon; David Cunningham; Andrew R Norman; Bhawna Sirohi; Jacqui Oates; Geoffrey Chong
The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract.
British journal of cancer 2007;96(8):1178-82.
2007: Dow-Mu Koh; Gina Brown; Ziad Meer; Andrew R Norman; Janet E Husband
Diagnostic accuracy of rim and segmental MRI enhancement of colorectal hepatic metastasis after administration of mangafodipir trisodium.
AJR. American journal of roentgenology 2007;188(2):W154-61.
2007: Usman Khalid; A Spiro; Christine Baldwin; B Sharma; Camilla McGough; Andrew R Norman; Tim Eisen; M E R O'Brien; D Cunningham; H J N Andreyev
Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2007;15(1):39-46.
2006: Christine Baldwin; Camilla McGough; Andrew R Norman; Gary S Frost; D C Cunningham; H J N Andreyev
Failure of dietetic referral in patients with gastrointestinal cancer and weight loss.
European journal of cancer (Oxford, England : 1990) 2006;42(15):2504-9.
2006: M Trumper; Paul J Ross; David Cunningham; Andrew R Norman; R Hawkins; Matt Seymour; P Harper; Tim Iveson; Marianne Nicolson; Tamas Hickish
Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials.
European journal of cancer (Oxford, England : 1990) 2006;42(7):827-34.
2006: Ian Chau; David Cunningham; C Russell; Andrew R Norman; Tom Kurzawinski; P Harper; Phillip Harrison; Gary Middleton; F Daniels; Tamas Hickish; J Prendeville; Paul J Ross; Belinda A Theis; R Hull; M Walker; N Shankley; B Kalindjian; Gordon D Murray; A Gillbanks; James W Black
Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.
British journal of cancer 2006;94(8):1107-15.
2006: Usman Khalid; Camilla McGough; Claire Hackett; Peter Blake; Kevin J Harrington; Vincent S Khoo; Diana Tait; Andrew R Norman; H J N Andreyev
A modified inflammatory bowel disease questionnaire and the Vaizey Incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading.
International journal of radiation oncology, biology, physics 2006;64(5):1432-41.
2006: Ian Chau; Gina Brown; David Cunningham; Diana Tait; Andrew Wotherspoon; Andrew R Norman; Niall Tebbutt; Mark Hill; Paul J Ross; Alison Massey; Jacqui Oates
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(4):668-74.
2005: Zahra Rahemtulla; Christine Baldwin; Ayelet Spiro; Camilla McGough; Andrew R Norman; Gary Frost; David Cunningham; H J N Andreyev
The palatability of milk-based and non-milk-based nutritional supplements in gastrointestinal cancer and the effect of chemotherapy.
Clinical nutrition (Edinburgh, Scotland) 2005;24(6):1029-37.
2005: Nick R Maisey; Andrew R Norman; A Hill; Alison Massey; Jacqui Oates; David Cunningham
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.
British journal of cancer 2005;93(7):740-3.
2005: Geoffrey Chong; J L B Dickson; David Cunningham; Andrew R Norman; Sheela Rao; ME Hill; T J Price; Jacqui Oates; Niall Tebbutt
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
British journal of cancer 2005;93(5):510-4.
2005: J M Bowen; K Newbold; Peter Blake; G Wild; W Egner; Andrew R Norman; H J N Andreyev
Do serum levels of eosinophil granule-derived protein change in patients undergoing pelvic radiotherapy?
Clinical oncology (Royal College of Radiologists (Great Britain)) 2005;17(5):382-4.
2005: H J N Andreyev; Panagiotis Vlavianos; Peter Blake; David P Dearnaley; Andrew R Norman; Diana Tait
Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist?
International journal of radiation oncology, biology, physics 2005;62(5):1464-71.
2005: Dow-Mu Koh; Gina Brown; Larissa K Temple; H Blake; A Raja; Paul Toomey; N Bett; S Farhat; Andrew R Norman; I Daniels; Janet E Husband
Distribution of mesorectal lymph nodes in rectal cancer: in vivo MR imaging compared with histopathological examination. Initial observations.
European radiology 2005;15(8):1650-7.
2005: F V Negri; Andrew Wotherspoon; David Cunningham; Andrew R Norman; Geoffrey Chong; Paul J Ross
Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1305-10.
2005: Ian Chau; Andrew R Norman; David Cunningham; Tim Iveson; Mark Hill; Tamas Hickish; Fiona J Lofts; Duncan I Jodrell; Andrew Webb; Diana Tait; Paul J Ross; Pat Shellito; Jacqueline R Oates
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(11):1551-9.
2005: Matthew Ng; David Cunningham; Andrew R Norman
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC).
European journal of cancer (Oxford, England : 1990) 2005;41(11):1542-6.
2005: Kate Sumpter; Catherine Harper-Wynne; David Cunningham; Sheela Rao; Niall Tebbutt; Andrew R Norman; C Ward; Tim Iveson; Marianne Nicolson; Tamas Hickish; Mark Hill; Jacqui Oates
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.
British journal of cancer 2005;92(11):1976-83.
2005: Sheela Rao; David Cunningham; R E Hawkins; ME Hill; D Smith; F Daniel; Paul J Ross; Jacqui Oates; Andrew R Norman
Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.
British journal of cancer 2005;92(9):1650-4.
2005: M Ng; J Waters; David Cunningham; Ian Chau; Alan Horwich; Mark Hill; Andrew R Norman; Andrew Wotherspoon; Daniel Catovsky
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
British journal of cancer 2005;92(8):1352-7.
2005: Ian Chau; Andrew R Norman; David Cunningham; Diana Tait; Paul J Ross; Tim Iveson; Mark Hill; Tamas Hickish; Fiona J Lofts; Duncan I Jodrell; Andrew Webb; Jacqueline R Oates
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(4):549-57.
2004: Ian Chau; Andrew R Norman; David Cunningham; Justin S Waters; C Topham; Gary Middleton; Mark Hill; Paul J Ross; R Katopodis; G Stewart; Jacqueline R Oates
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
British journal of cancer 2004;91(8):1453-8.
2004: Ourania Katopodis; Paul Ross; Andrew R Norman; Jacqui Oates; David Cunningham
Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital.
European journal of cancer (Oxford, England : 1990) 2004;40(15):2230-6.
2004: Sheela Rao; David Cunningham; T Price; ME Hill; Paul J Ross; Niall Tebbutt; Andrew R Norman; Jacqui Oates; P Shellito
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.
British journal of cancer 2004;91(5):839-43.
2004: Rohit Lal; James Dickson; David Cunningham; Ian Chau; Andrew R Norman; Paul J Ross; Clare Topham; Gary Middleton; Mark Hill; Jacqui Oates
A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3023-31.
2004: Francesca Negri; Antonino Musolino; David Cunningham; Ugo Pastorino; George Ladas; Andrew R Norman
Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy.
Clinical colorectal cancer 2004;4(2):101-6.
2004: Ian Chau; Andrew R Norman; David Cunningham; Justin S Waters; Jacqui Oates; Paul J Ross
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2395-403.
2004: Ian Chau; Mark J Allen; David Cunningham; Andrew R Norman; Gina Brown; Hugo Ford; Niall Tebbutt; Diana Tait; Mark Hill; Paul J Ross; Jacqui Oates
The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1420-9.
2004: Dow-Mu Koh; Gina Brown; Louis Temple; Asraf Raja; Paul Toomey; Nicholas Bett; Andrew R Norman; Janet E Husband
Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings--initial observations.
Radiology 2004;231(1):91-9.
2004: Timothy J Price; Paul J Ross; Tamas Hickish; Diana Tait; Andrew R Norman; Hugo Ford; Gary Middleton; Kate Sumpter; Mark Hill; Jacqui Oates; David Cunningham
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.
Clinical colorectal cancer 2004;3(4):235-42.
2004: Laura Assersohn; Gina Brown; David Cunningham; C Ward; Jacqui Oates; Justin S Waters; ME Hill; Andrew R Norman
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(1):64-9.
2003: B Gami; Kevin Harrington; Peter Blake; David P Dearnaley; Diana Tait; J Davies; Andrew R Norman; H J N Andreyev
How patients manage gastrointestinal symptoms after pelvic radiotherapy.
Alimentary pharmacology & therapeutics 2003;18(10):987-94.
2003: Cheng Yeoh; Ian Chau; David Cunningham; Andrew R Norman; Mark Hill; Paul J Ross
Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
Clinical colorectal cancer 2003;3(2):102-7.
2003: Kate Sumpter; Catherine Harper-Wynne; David Cunningham; A Gillbanks; Andrew R Norman; Mark Hill
Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2003;15(5):221-6.
2003: Ian Chau; R Jones; David Cunningham; Andrew Wotherspoon; Nick R Maisey; Andrew R Norman; PARESH JAIN; L Bishop; Alan Horwich; Daniel Catovsky
Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
British journal of cancer 2003;89(1):36-42.
2003: A Saini; Andrew R Norman; David Cunningham; Ian Chau; Mark Hill; Diana Tait; Tamas Hickish; Tim Iveson; Fiona J Lofts; Duncan I Jodrell; Paul J Ross; Jacqui Oates
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.
British journal of cancer 2003;88(12):1859-65.
2003: H J N Andreyev; Robert Benamouzig; M Beranek; P Clarke; D Cunningham; Andrew R Norman; W Giaretti; Anton F P M de Goeij; B J Iacopetta; Eric Jullian; Koviljka Krtolica; J Q Lee; S T Wang; N Lees; F Al-Mulla; O Muller; M Pauly; V Pricolo; A Russo; C Troungos; N Urosevic; R Ward
Mutant K-ras2 in serum.
Gut 2003;52(6):915-6.
2003: Niall Tebbutt; Andrew R Norman; David Cunningham; M Allen; Ian Chau; Jacqui Oates; Mark Hill
Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil.
British journal of cancer 2003;88(10):1510-5.
2003: Laura Assersohn; Andrew R Norman; David Cunningham; Tim Iveson; Matt Seymour; Tamas Hickish; Alison Massey; Yvonne Prior; ME Hill
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1121-8.
2003: Ian Chau; M Allen; David Cunningham; Diana Tait; Gina Brown; Mark Hill; Kate Sumpter; A Rhodes; Andrew Wotherspoon; Andrew R Norman; A Hill; Alison Massey; Yvonne Prior
Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer.
British journal of cancer 2003;88(7):1017-24.
2003: Niall Tebbutt; Andrew R Norman; D Cunningham; M E Hill; D Tait; Jacqui Oates; S Livingston; J Andreyev
Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases.
Gut 2003;52(4):568-73.
2003: Ian Chau; Mark Harries; David Cunningham; Mark Hill; Paul J Ross; Caroline D Archer; Andrew R Norman; Andrew Wotherspoon; Dow-Mu Koh; Kairen Gill; Maggie Uzzell; Yvonne Prior; Daniel Catovsky
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
British journal of haematology 2003;120(6):970-7.
2003: Ian Chau; M T Kelleher; David Cunningham; Andrew R Norman; Andrew Wotherspoon; PA Trott; P Rhys-Evans; G Querci Della Rovere; Gina Brown; M Allen; Justin S Waters; S Haque; T Murray; L Bishop
Rapid access multidisciplinary lymph node diagnostic clinic: analysis of 550 patients.
British journal of cancer 2003;88(3):354-61.
1999: David P Dearnaley; V S Khoo; Andrew R Norman; L Meyer; AE Nahum; Diana Tait; John Yarnold; A Horwich
Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial.
Lancet 1999;353(9149):267-72.
1998: D C Farrugia; Andrew R Norman; David Cunningham
Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 1998;34(7):987-91.
1998: H J N Andreyev; Andrew R Norman; David Cunningham; Jacqueline R Oates; Paul A Clarke
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.
Journal of the National Cancer Institute 1998;90(9):675-84.
1998: H J N Andreyev; Andrew R Norman; Jacqui Oates; David Cunningham
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
European journal of cancer (Oxford, England : 1990) 1998;34(4):503-9.
1997: H J N Andreyev; J V Tilsed; D Cunningham; S A Sampson; Andrew R Norman; H J Schneider; Paul A Clarke
K-ras mutations in patients with early colorectal cancers.
Gut 1997;41(3):323-9.
1997: Paul J Ross; Andrew Webb; David Cunningham; JA Prendiville; Andrew R Norman; Jacqui Oates
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: the Royal Marsden Hospital experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(2):111-5.
1997: H J Schneider; S A Sampson; D Cunningham; Andrew R Norman; H J N Andreyev; J V Tilsed; Paul A Clarke
Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas.
British journal of cancer 1997;75(3):427-31.
1996: D C Farrugia; Andrew R Norman; M C Nicolson; M Gore; E O Bolodeoku; Andrew Webb; David Cunningham
Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits.
European journal of cancer (Oxford, England : 1990) 1996;32A(13):2256-61.
1996: A Bamias; M E Hill; David Cunningham; Andrew R Norman; F Y Ahmed; Andrew Webb; M Watson; A S Hill; M C Nicolson; M E R O'Brien; T C Evans; V Nicolson
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Cancer 1996;77(10):1978-85.
1996: Paul J Ross; Andrew Webb; David Cunningham; J Prendiville; Andrew R Norman; Jacqui Oates
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience.
The Journal of infusional chemotherapy 1996;6(3):141-4.
1995: H J N Andreyev; Andrew R Norman; David Cunningham; A R Padhani; A S Hill; Paul J Ross; Andrew Webb
Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF).
European journal of cancer (Oxford, England : 1990) 1995;31A(13-14):2209-14.
1995: H J N Andreyev; P Scott-Mackie; David Cunningham; V Nicolson; Andrew R Norman; S S Badve; A Iveson; M C Nicolson
Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(6):1486-92.
1995: David Cunningham; M E Hill; M Watson; Andrew R Norman
Survival after systemic therapy for metastatic colorectal cancer.
Lancet 1995;345(8945):328-9.
1995: S J Vinnicombe; Andrew R Norman; V Nicolson; J E Husband
Normal pelvic lymph nodes: evaluation with CT after bipedal lymphangiography.
Radiology 1995;194(2):349-55.